Coronavirus Vaccine Sales Key to Moderna's (MRNA) Q3 Earnings
Zacks Investment Research | Nov 01, 2021 11:10PM ET
Moderna (NASDAQ:MRNA), Inc. industry .
Moderna has a few strategic alliances with pharma companies for the development of some of its pipeline candidates. These alliances generate collaboration revenues for the company. The Zacks Consensus Estimate for collaboration revenues is pegged at $16.55 million for the third quarter.
Apart from mRNA-1273, Moderna is engaged in developing several other mRNA-based products targeting a wide variety of diseases. During the third quarter, the company initiated three new phase I/II studies to evaluate a flu vaccine candidate, an autoimmune therapeutic candidate and an investigational mRNA therapeutic for methylmalonic acidemia. The company initiated a phase III study in October to evaluate its cytomegalovirus vaccine candidate. The company is also conducting clinical studies on its COVID-19 vaccine to develop it for new population or variant-specific booster doses. The company is also focused on capacity expansion to support manufacturing and supply of its COVID-19 vaccine and booster doses, and other mRNA-based pipeline candidates.
These ongoing clinical studies, preparation for the late-stage CMV vaccine study, and capacity expansion are likely to have driven operating expense higher for the company during the third quarter. (Read more: .
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.